Nanmo Biotech Investor Relations Activity Record Form 2024-007
Announcement of Resolutions of the 16th Meeting of the Third Board of Directors
Nanmo Biotech: Announcement on holding the 2024 semi-annual results briefing
Announcement on holding the 2024 semi-annual results briefing
Nanmo Biotech: China International Finance Corporation\'s Verification Report on the Shareholders of Shanghai Nanfang Model Biotechnology Co., Ltd. requesting quotations and transfers of shares to specific institutional investors
China International Finance Corporation Verification Report on Shareholders of Shanghai Southern Model Biotechnology Co., Ltd. requesting quotations and transfers of shares to specific institutional investors
China International Finance Corporation\'s inspection opinions on the qualifications of shareholders of Shanghai Southern Model Biotechnology Co., Ltd. to inquire and transfer shares to specific institutional investors
Nanmo Biotech Investor Relations Activity Record Form 2024-006
Haitong Securities Co., Ltd.\'s 2024 semi-annual follow-up report on the continuous supervision of Shanghai Southern Model Biotechnology Co., Ltd.
Special Report on the Deposit and Use of Funds Raised for the Semi-Annual Year of 2024
Announcement of Resolutions of the 12th Meeting of the Third Board of Supervisors
Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Focus on Rewards” Action Plan
Announcement of the resolution of the 14th meeting of the 3rd board of directors.
Investor Relations Activity Record Form of Nanmo Biology 2024-005
Audit opinion on differentiated dividends of Shanghai Southern Model Bio-Technology Co., Ltd. by Haitong Securities Co., Ltd.
Nanmo Biotech Investor Relations Activity Record Form 2024-004
Announcement on attending the 2023 Biological Products Special Group Results Briefing and the 2024 First Quarter Results Briefing
Haitong Securities Co., Ltd.'s 2023 Annual Follow-up Report on the Continuous Supervision of Shanghai Southern Model Biotechnology Co., Ltd.
Haitong Securities Co., Ltd. report on the 2023 continuous supervision site inspection report of Shanghai Southern Model Biotechnology Co., Ltd.
Independent Director Work System (Revised in April 2024)
No Data
No Data